Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas ; volume:10 ; number:1 ; day:19 ; month:6 ; year:2017 ; pages:1-10 ; date:12.2017
Journal of hematology & oncology ; 10, Heft 1 (19.6.2017), 1-10, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Laroche-Clary, Audrey
- Beteiligte Personen und Organisationen
-
Chaire, Vanessa
Algéo, Marie-Paule
Derieppe, Marie-Alix
Loarer, François L.
Italiano, Antoine
SpringerLink (Online service)
- DOI
-
10.1186/s13045-017-0482-3
- URN
-
urn:nbn:de:1111-201709104746
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Laroche-Clary, Audrey
- Chaire, Vanessa
- Algéo, Marie-Paule
- Derieppe, Marie-Alix
- Loarer, François L.
- Italiano, Antoine
- SpringerLink (Online service)
Ähnliche Objekte (12)
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
The role of targeting CDK4/6 in cancer immunotherapy
Targeting MDM2, the antagonist of the tumor suppressor p53
CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
MiR-181b sensitizes glioma cells to teniposide by targeting MDM2
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
The role of targeting CDK4/6 in cancer immunotherapy
Targeting MDM2, the antagonist of the tumor suppressor p53
CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
MiR-181b sensitizes glioma cells to teniposide by targeting MDM2
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Overdiagnosis of atypical lipomatous tumors/well-differentiated liposarcomas by morphological diagnosis using only HE stained specimens: a case–control study with MDM2/CDK4 immunostaining and MDM2/CDK4 fluorescence in situ hybridization
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
The role of targeting CDK4/6 in cancer immunotherapy
Targeting MDM2, the antagonist of the tumor suppressor p53
CDK4 is co-amplified with either TP53 promoter gene fusions or MDM2 through distinct mechanisms in osteosarcoma
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Low-Grade Uterine Adenosarcoma with Overexpression of MDM2 and CDK4 by Immunohistochemistry: A Case Report and Literature Review
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer